tradingkey.logo
tradingkey.logo
Search

Caribou Biosciences Inc

CRBU
Add to Watchlist
1.640USD
0.0000.00%
Close 06/18, 16:00ETQuotes delayed by 15 min
162.66MMarket Cap
LossP/E TTM

Earnings Forecast

Currency: USD Updated: 2026-06-18
Previous score
8.75
Change
0
The current earnings forecast score of Caribou Biosciences Inc is 8.75, ranking 63 out of 389 in the Biotechnology & Medical Research industry. The average price target is 8.50, with a high of 32.00 and a low of 4.00.

Analyst Rating

Based on 8 analysts
Buy
Current Rating
12.125
Target Price
+639.33%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Caribou Biosciences Inc
CRBU
8
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

What is Caribou Biosciences Inc's expected revenue for the next quarter?

Caribou Biosciences Inc's expected revenue is 2.28M.

What is Caribou Biosciences Inc's price target?

Analysts forecast that Caribou Biosciences Inc's price target is USD 8.50, with the highest forecast at USD 32.00 and the lowest forecast at USD 4.00.

How have Caribou Biosciences IncCRBU's recent earnings per share performed?

The market expectation was USD -0.26, while Caribou Biosciences IncCRBU's earnings per share (EPS) for the previous quarter was USD -0.28. EPS for the next quarter is expected at USD -0.32.

What is the analyst rating for Caribou Biosciences Inc?

Based on the ratings of Caribou Biosciences Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
KeyAI